This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neu, H. C.
Right arrow Articles by Aswapokee, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neu, H. C.
Right arrow Articles by Aswapokee, P.

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1979 August; 16(2): 141-149
Copyright © 1979, American Society for Microbiology. All Rights Reserved.

Antibacterial Activity of a New 1-Oxa Cephalosporin Compared with That of Other ß-Lactam Compounds

Harold C. Neu, Nalinee Aswapokee, Kwung P. Fu and Prasit Aswapokee

1 Division of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, New York, New York 10032

ABSTRACT

The in vitro activity of (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-[[(1-methyl -1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo-[4.2.0]oct-2-ene -2-carboxylic acid was tested against isolates of gram-positive and negative bacteria and compared with those of cephalothin, cefuroxime, cefamandole, cefoxitin, cefotaxime, and carbenicillin. The compound was less active than the other compounds when tested against Staphylococcus aureus and Staphylococcus epidermidis. It had equal or slightly less activity than did cefotaxime when tested against members of the Enterobacteriaceae, but was 8- to 32-fold more active than the other cephalosporins against the Enterobacteriaceae, inhibiting most isolates at concentrations less than 0.5 µg/ml. The compound was twofold more active than cefotaxime and cefoxitin against Bacteroides, and it was twofold more active than cefotaxime and fourfold more active than carbenicillin against Pseudomonas aeruginosa. In vitro activity did not correlate with either the presence or type of ß-lactamase in either Enterobacteriaceae or Pseudomonas. The compound showed minimal synergy when combined with aminoglycosides or carbenicillin.

Antimicrob Agents Chemother. 1979 August; 16(2): 141-149
Copyright © 1979, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Fry, D. E., Trachtenberg, L., Polk, H. C. Jr (1986). Serum Kinetics of Intraperitoneal Moxalactam. Arch Surg 121: 282-284 [Abstract]  
  • Fainstein, V., Bodey, G. P., Bolivar, R., Elting, L., McCredie, K. B., Keating, M. J. (1984). Moxalactam Plus Ticarcillin or Tobramycin for Treatment of Febrile Episodes in Neutropenic Cancer Patients. Arch Intern Med 144: 1766-1770 [Abstract]  
  • Fett, D. R., Silverman, C. A., Yoshizumi, M. O. (1984). Moxalactam Retinal Toxicity. Arch Ophthalmol 102: 435-438 [Abstract]  
  • NEU, H. C. (1982). The New Beta-Lactamase-Stable Cephalosporins. ANN INTERN MED 97: 408-419 [Abstract]  
  • RAHAL, J. J., SIMBERKOFF, M. S. (1982). Host Defense and Antimicrobial Therapy in Adult Gram-Negative Bacillary Meningitis. ANN INTERN MED 96: 468-474 [Abstract]  
  • YU, V. L. (1981). Enterococcal Superinfection and Colonization After Therapy with Moxalactam, a New Broad-Spectrum Antibiotic. ANN INTERN MED 94: 784-785 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»